MedTrace Logo

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

NCT06167785 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-06-19

No results posted yet for this study

Summary

This is a phase ll study of participants with large B Cell lymphoma previously treated with anti-CD19 Chimeric antigen receptor (CAR-T) therapy. The purpose of the study is to to evaluate the efficacy of zanubrutinib and tislelizumab in patients with progressive lymphoma post anti-CD 19 CAR-T failure.

Conditions

Interventions

DRUG

Tislelizumab

Tislelizumab 200mg intravenously every 3 weeks

DRUG

Zanubrutinib

Zanubrutinib 160 mg oral twice daily

DRUG

Tislelizumab + Zanubrutinib

Tislelizumab 200mg intravenously day 1 of each cycle every 3 weeks + Zanubrutinib 160 mg oral twice daily starts day 1 of each cycle

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • John Kuruvilla, FRCPC · University Health Network, Toronto

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-04
Primary Completion
2026-04-30
Completion
2027-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06167785 on ClinicalTrials.gov